Putting Covid vaccines into pills could soon move from dream to reality after a Sussex-based biotech signed an agreement with a US pharmaceutical company to test the technology in clinical trials. The technology is now being used by ImmunityBio, a Californian company developing a vaccine against Covid after signing a licensing agreement with iosBio. Clinical trials in monkeys have shown the oral vaccine made using iosBio technology to be highly effective, while the jab version is already in phase two/three trials. The oral vaccine will begin clinical trials on Americans this month and ImmunityBio is applying for regulatory approval to run trials in the UK. […] ImmunityBio’s vaccine is a viral vector vaccine, and unlike other candidates it contains two different spike proteins, Mr Channing said.
Click here to read the full article